About

About FYR FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, better trials, better drugs and better outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCsTM, to enrich extracellular vesicles from diseased cells and reveal a treasure trove of proteins and nucleic acids. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential treatment options. The unparalleled view provided by FYR’s multiomics approach can transform personalized patient care, from screening through therapy selection and monitoring.